Login / Signup

Xanthohumol Microbiome and Signature in Healthy Adults (the XMaS Trial): Safety and Tolerability Results of a Phase I Triple-Masked, Placebo-Controlled Clinical Trial.

Blake O LangleyJennifer Joan RyanDouglas HanesJohn PhippsEmily StackThomas O MetzJan Frederick StevensRyan D Bradley
Published in: Molecular nutrition & food research (2021)
Over an eight-week period, 24 mg daily xanthohumol was safe and well-tolerated by healthy adults.
Keyphrases
  • placebo controlled
  • phase ii
  • phase iii
  • double blind
  • clinical trial
  • study protocol
  • open label
  • phase ii study
  • physical activity
  • randomized controlled trial
  • squamous cell carcinoma
  • radiation therapy